WO1992018508A1

WO1992018508A1 - New cephem compounds

Info

Publication number: WO1992018508A1
Application number: PCT/JP1992/000472
Authority: WO
Inventors: Kazuo Sakane; Hideaki Yamanaka; Minoru Sakurai
Original assignee: Fujisawa Pharmaceutical Co., Ltd.
Priority date: 1991-04-15
Filing date: 1992-04-14
Publication date: 1992-10-29
Also published as: JPH06509550A; GB9107973D0

Abstract

New cephem compounds of formula (I) wherein R1 is amino or protected amino, Z is N or CH, R2 is hydrogen or an organic group, R3 is lower alkyl, R4 is lower alkyl, A is lower alkylene, R5 is hydroxy or protected hydroxy, and R6 is carboxy, protected carboxy, etc., and pharmaceutically acceptable salts thereof which are useful as a medicament.

Description

DESCRIPTION NEW CEPHEM COMPOUNDS

TECHNICAL FIELD

This invention relates to new cephem compounds and pharmaceutically acceptable salts thereof which are useful as a medicament.

BACKGROUND ART

Some cephem compounds have been known as described, for example, in U.S. Patent 4,457,929 and European Patent Application Publication No. 0345671 A2.

DISCLOSURE OF INVENTION

The present invention relates to new cephem compounds and pharmaceutically acceptable salts thereof. More particularly, it relates to new cephem compounds and pharmaceutically acceptable salts thereof, which have antimicrobial activities, to processes for preparation thereof, to pharmaceutical composition comprising the same, and to a method for treating infectious diseases. in human being and animals.

Accordingly, one object of the present invention is to provide the cephem compounds and pharmaceutically acceptable salts thereof, which are highly active against a number of pathogenic microorganisms.

Another object of the present invention is to provide processes for the preparation of the cephem compounds and salts thereof.

A further object of the present invention is to provide pharmaceutical composition comprising, as an active ingredient, said cephem compounds or their pharmaceutically acceptable salts.

Still further object of the present invention is to provide a method for treating infectious diseases caused by pathogenic microorganisms , which comprises

administering said cephem compounds to infected human being or animals.

The object cephem compounds of the present invention are novel and can be represented by the following general formula (I) :

wherein R¹ is amino or protected amino,

Z is N or CH,

R² is hydrogen or an organic group,

R³ is lower alkyl,

R⁴ is lower alkyl,

A is lower alkylene,

R⁵ is hydroxy or protected hydroxy, and

R⁶ is carboxy, protected carboxy, carbamoyl,

or mono or di substituted carbamoyl.

The object compound (I) of the present invention can be prepared by the following processes. Process (1)

Process (2)

Process (3)

Process (4)

Process (5)

wherein R¹, R², R³, R⁴, R⁵, R⁶, Z and A are each as defined above.

R_a ² is protected carboxy(lower)alkyl, R² _b is carboxy(lower)alkyl,

R⁵ _a is protected hydroxy,

R⁶ _a is protected carboxy and

Y is a leaving group.

The starting compounds (II) and (V) or salts thereof can be prepared by the following Processes.

Process (A)

Process (B)

Process (C)

Process (D)

Process (E)

Process (F)

Process (G)

wherein R³, R⁴, R⁵, R_a ⁵, R⁶, R_a ⁶, A and Y are each as defined above,

R⁷ is hydrogen or lower alkyl,

R⁸ is hydrogen or lower alkyl,

R⁹ is amino or protected amino and

R_a ⁹ is protected ammo.

Regarding the compounds (I), (Ia)~(If), (III) and (IV), it is to be understood that said compounds include syn isomer, anti isomer and a mixture thereof.

For example, with regard to the object compound (I), syn isomer means one geometrical isomer having the partial structure represented by the following formula :

(wherein R ¹, R² and 2 are each as defined above) and anti isomer means the other geometrical isomer having the partial structure represented by the following formula :

(wherein R ¹, R² and Z are each as defined above), and all of such geometrical isomers and mixture thereof are included within the scope of this invention.

In the present specification and claim, the partial structure of these geometrical isomers and mixture thereof are represented for convenient sake by the following formula :

(wherein R¹, R¹ and Z are each as defined above).

In the above and subsequent descriptions of the present specification, suitable examples and illustrations of the various definitions which the present invention include within the scope thereof are explained in detail as follows.

The term "lower" is intended to mean 1 to 6 carbon atom(s) unless otherwise indicated.

Suitable "lower alkyl" may include straight or

branched one such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, pentyl, hexyl, and the like.

Suitable "protected amino" may include an acylamino or an amino group substituted by a conventional protecting group such as ar(lower)alkyl which may have suitable substituent(s) (e.g. benzyl, trityl, etc.) or the like.

Suitable "acyl moiety" in the term "acylamino" may include carbamoyl, aliphatic acyl group and acyl group containing an aromatic or heterocyclic ring. And, suitable examples of the said acyl may be lower alkanoyl (e.g.

formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, oxalyl, succinyl, pivaloyl, etc.); lower

alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl,

tertiarybutoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, etc.); lower alkanesulfonyl (e.g. mesyl, ethanesulfonyl, propanesulfonyl, isopropanesulfonyl, butanesulfonyl, etc.); arenesulfonyl (e.g. benzenesulfonyl, tosyl, etc.); aroyl (e.g. benzoyl, toluoyl, xyloyl, naphthoyl, phthaloyl, indancarbonyl, etc.); ar( lower)alkanoyl (e.g. phenylacetyl. phenylpropionyl, etc.); ar(lower)alkoxycarbonyl (e.g. benzyloxycarbonyl, phenethyloxycarbonyl, etc.), and the like. The acyl moiety as stated above may have suitable substituent(s) such as halogen (e.g. chlorine, bromine, iodine or fluorine) or the like.

Suitable "organic group" may include lower alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, neopentyl, tert-pentyl, hexyl, etc.), mono(or di or tri)halo(lower)alkyl (e.g.

chloromethyl, dichloromethyl, trichloromethyl,

bromomethyl, chloroethyl, dichloroethyl, trichloroethyl, fluoroethyl, trifluoroethyl, etc.),

lower alkenyl (e.g., vinyl, 1-propenyl, allyl,

1-methylallyl, 1 or 2 or 3-butenyl, 1 or 2 or 3 or

4-pentenyl, 1 or 2 or 3 or 4 or 5-hexenyl, etc.),

lower alkynyl (e.g., ethynyl, 1-propynyl, propargyl, 1-methylpropargyl, 1 or 2 or 3-butynyl, 1 or 2 or 3 or 4-pentynyl, 1 or 2 or 3 or 4 or 5-hexynyl, etc.),

aryl (e.g., phenyl, naphthyl, etc.),

ar(lower)alkyl such as phenyl(lower)alkyl (e.g., benzyl, phenethyl, phenylpropyl, etc.),

carboxy(lower)alkyl wherein lower alkyl moiety can be referred to the ones as exemplified above, protected carboxy(lower)alkyl wherein lower alkyl moiety can be referred to the ones as exemplified above and protected carboxy moiety can be referred to the ones as exemplified below, and the like.

Suitable "protected carboxy" and "protected carboxy moiety" in the term "protected carboxy(lower)alkyl" may include esterified carboxy and the like. And suitable examples of said ester may be the ones such as lower alkyl ester (e.g., methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, t-butyl ester, pentyl ester, t-pentyl ester, hexyl ester, etc.); lower alkenyl ester (e.g., vinyl ester, allyl ester. etc.); lower alkynyl ester (e.g., ethynyl ester, propynyl ester, etc.); lower alkoxyalkyl ester (e.g., methoxymethyl ester, ethoxymethyl ester, isopropoxymethyl ester,

1-methoxyethyl ester, 1-ethoxyethyl ester, etc.);

lower alkylthioalkyl ester (e.g., methylthiomethyl ester, ethylthiomethyl ester, ethylthioethyl ester,

isopropylthiomethyl ester, etc.);

mono(or di or tri)halo(lower)alkyl ester (e.g. 2-iodoethyl ester, 2,2,2-trichloroethyl ester, etc.);

lower alkanoyloxy(lower)alkyl ester (e.g., acetoxymethyl ester, propionyloxymethyl ester, butyryloxymethyl ester, valeryloxymethyl ester, pivaloyloxymethyl ester,

hexanoyloxymethyl ester, 2-acetoxyethyl ester,

2-propionyloxyethyl ester, etc.); lower

alkanesulfonyl(lower)alkyl ester (e.g. mesylmethyl ester, 2-mesylethyl ester etc.); ar(lower)alkyl ester, for example, phenyl(lower)alkyl ester which may have one or more suitable substituent(s) (e.g., benzyl ester,

4-methoxybenzyl ester, 4-nitrobenzyl ester, phenethyl ester, trityl ester, benzhydryl ester,

bis (methoxyphenyl)methyl ester, 3,4-dimethoxybenzyl ester, 4-hydroxy-3,5-di-t-butylbenzyl ester, etc.);

aryl ester which may have one or more suitable

substituent(s) such as substituted or unsubstituted phenyl ester ( e . g. , phenyl ester, tolyl ester , t-butylphenyl ester, xylyl ester, mesityl ester, cumenyl ester,

4-chlorophenyl ester, 4-methoxyphenyl ester, etc.);

tri(lower)alkyl silyl ester; lower alkylthioester (e.g. methylthioester, ethylthioester, etc.) and the like.

Suitable "lower alkylene" may include methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene and the like.

Suitable "protective group" in the "protected hydroxy group" may include acyl as mentioned above,

phenyl(lower)alkyl which may have one or more suitable substituent(s) (e.g. benzyl, 4-methoxybenzyl, etc.), tetrahydropyranyl and the like.

Suitable mono or di substituted carbamoyl may be mono or di(lower)alkylcarbamoyl (e.g. methylcarbamoyl,

dimethylcarbamoyl, ethylcarbamoyl, diethylcarbaraoyl, N-methyl-N-ethylcarbamoyl, propylcarbamoyl,

dipropylcarbamoyl, isopropylcarbamoyl, butylcarbamoyl, pentylcarbamoyl, hexylcarbamoyl, etc.), and the like.

Suitable "leaving group" may be halogen [e.g. chlorine, bromine, iodine, etc.], acyloxy such as

sulfonyloxy [e.g. benzenesulfonyloxy, tosyloxy, mesyloxy, etc.], lower alkanoyloxy [e.g. acetyloxy, propionyloxy, etc.] or the like.

Suitable pharmaceutically acceptable salts of the object compound (I) are conventional non-toxic salts and include a metal salt such as an alkali metal salt [e.g. sodium salt, potassium salt, etc.] and an alkaline earth metal salt [e.g. calcium salt, magnesium salt, etc.], an ammonium salt, an organic base salt [e.g. trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.], an organic acid salt [e.g. formate, acetate, trifluoroacetate, maleate, tartrate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.], an inorganic acid salt [e.g. hydrochloride, hydrobromide, sulfate, phosphate, etc.], a salt with an amino acid [e.g.

arginine salt, aspartic acid salt, glutamic acid salt, etc.], and the like. The processes for preparing the object and starting compounds of the present invention are explained in detail in the following.

Process (1)

The compound (I) or a salt thereof can be prepared by reacting the compound (II) or its reactive derivative at the amino group or a salt thereof with the compound (III) or its reactive derivative at the carboxy group or a salt thereof.

Suitable reactive derivative at the amino group of the compound (II) may include Schiff s base type imino or its tautomeric enamine type isomer formed by the reaction o the compound (II) with a carbonyl compound such as aldehyde ketone or the like; a silyl derivative formed by the reaction of the compound ( II ) with a silyl compound such as bis ( trimethylsilyl ) acetamide , mono( trimethylsilyl)acetamide [e.g. N-(trimethylsilyl)acetamide], bis(trimethylsilyl)urea or the like; a derivative formed by reaction of

the compound (II) with phosphorus trichloride or phosgene, and the like.

Suitable reactive derivative at the carboxy group of the compound (III) may include a conventional one used in a β-lactam chemistry, an acid halide, an acid anhydride, an activated amide, an activated ester, and the like.

Suitable examples of the reactive derivatives may be an acid chloride; an acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid [e.g.

dialkylphosphoric acid, phenylphosphoric acid,

diphenylphosphoric acid, dibenzylphosphoric acid,

halogenated phosphoric acid, etc.], dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, sulfuric acid, sulfonic acid [e.g. methanesulfonic acid, etc.], aliphatic carboxylie acid [e.g. acetic acid, propionic acid, butyric acid, isobutyric acid, pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid, etc.] or aromatic carboxylic acid [e.g. benzoic acid, etc.]; a symmetrical acid anhydride;

an activated amide with imidazole, 4-substituted

imidazole, dimethylpyrazole, triazole or tetrazole; or an activated ester [e.g. cyanomethyl ester, methoxymethyl ester, dimethyliminomethyl [(CH₃)₂N⁺=CH-] ester, vinyl ester, propargyl ester, p-nitrophenyl ester,

2,4-dinitrophenyl ester, trichlorophenyl ester,

pentachlorophenyl ester, mesylphenyl ester,

phenylazophenyl ester, phenyl thioester, p-nitrophenyl thioester, p-cresyl thioester, benzothiazolyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolyl thioester, etc.], or an ester with a N-hydroxy compound [e.g. N,N-dimethylhydroxylamine, 1-hydroxy-2-(1H)-pyridone, N-hydroxysuccinimide,

N-hydroxyphthalimide, 1-hydroxy-1H-benzotriazole, etc.], and the like. These reactive derivatives can optionally be selected from them according to the kind of the compound (III) to be used.

The reaction is usually carried out in a conventional solvent such as water, alcohol [e.g. methanol, ethanol, etc.], acetone, dioxane, acetonitrile, chloroform,

methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction. These conventional solvent may also be used in a mixture with water.

In this reaction, when the compound (III) is used in a free acid form or its salt form, the reaction is

preferably carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide;

N-cyclohexyl-N'-morpholinoethylcarbodiimide;

N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide;

N,N'-diethylcarbodiimide, N,N'-diisopropylcarbodiimide;

N-ethyl-N'-{3-dimethylaminopropyl)carbodiimide;

N,N'-carbonyl-bis(2-methylimidazole); pentamethyleneketene-N-cyclohexylimine;

diphenylketene-N-cyclohexylimine; ethoxyacetylene;

1-alkoxy-1-chloroethylene; trialkyl phosphite; ethyl

polyphosphate; isopropyl polyphosphate; phosphorus oxychloride (phosphoryl chloride); phosphorus trichloride; thionyl chloride; oxalyl chloride; lower alkyl haloformate [e.g. ethyl chloroformate, isopropyl chloroformate, etc.]; triphenylphosphine; 2-ethyl-7-hydroxybenzisoxazolium salt; 2-ethyl-5-(m-sulfophenyl)isoxazolium hydroxide

intramolecular salt; 1-(p-chlorobenzenesulfonyloxy)-6- chloro-1H-benzotriazole; so-called Vilsmeier reagent prepared by the reaction of N,N-dimethylformamide with thionyl chloride, phosgene, trichloromethyl chloroformate, phosphorus oxychloride, etc.; or the like.

The reaction may also be carried out in the presence of an inorganic or organic base such as an alkali metal bicarbonate, tri(lower)alkylamine, pyridine,

N-(lower)alkylmorpholine, N,N-di(lower)alkylbenzylamine, or the like.

The reaction temperature is not critical, and the reaction is usually carried out under cooling to warming.

Process ( 2 )

The compound (Ib) or a salt thereof can be prepared by subjecting the compound (Ia) or a salt thereof to elimination reaction of the carboxy protective group in R_a ².

Suitable method of this elimination reaction may include conventional one such as hydrolysis, reduction and the like.

(i) For Hydrolysis :

The hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid.

Suitable base may include an inorganic base and an organic base such as an alkali metal [e.g. sodium,

potassium, etc.], an alkaline earth metal [e.g. magnesium, calcium, etc.], the hydroxide or carbonate or bicarbonate thereof, trialkylamine [e.g. trimethylamine,

triethylamine, etc.], picoline, 1,5-diazabicyclo[4.3.0]- non-5-ene, 1,4-diazabicyclo[2.2.2]octane,

1,8-diazabicyclo[5.4.0]undec-7-ene, or the like.

Suitable acid may include an organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.] and an inorganic acid [e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, etc.]. The eliminatio using Lewis acid such as trihaloacetic acid [e.g.

trichloroacetic acid, trifluoroacetic acid, etc.] or the like is preferably carried out in the presence of cation trapping agents [e.g. anisole, phenol, etc.].

The reaction is usually carried out in a solvent such as water, an alcohol [e.g. methanol, ethanol, etc.], methylene chloride, tetrahydrofuran, a mixture thereof or any other solvent which does not adversely influence the reaction. A liquid base or acid can be also used as the solvent. The reaction temperature is not critical and the reaction is usually carried out under cooling to warming. (ii) For reduction :

Reduction is carried out in a conventional manner, including chemical reduction and catalytic reduction.

Suitable reducing agents to be used in chemical

reduction are a combination of a metal (e.g. tin, zinc, iron, etc.) or metallic compound (e.g. chromium chloride, chromium acetate, etc.) and an organic or inorganic acid (e.g. formic acid, acetic acid, propionic acid,

trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.).

Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts (e.g.

platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.), palladium catalysts (e.g. spongy palladium, palladium black,

palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium

carbonate, etc.), nickel catalysts (e.g. reduced nickel, nickel oxide, Raney nickel, etc.), cobalt catalysts (e.g. reduced cobalt, Raney cobalt, etc.), iron catalysts (e.g. reduced iron, Raney iron, etc.) copper catalysts (e.g. reduced copper, Raney copper, Ullman copper, etc.) and the like. The reduction is usually carried out in a

conventional solvent which does not adversely influence the reaction such as water, methanol, ethanol, propanol, N,N-dimethylformamide, or a mixture thereof.

Additionally, in case that the above-mentioned acids to be used in chemical reduction are in liquid, they can also be used as a solvent. Further, a suitable solvent to be used in catalytic reduction may be the above-mentioned solvent, and other conventional solvent such as diethyl ether, dioxane, tetrahydrofuran, etc., or a mixture thereof.

The reaction temperature of this reduction is not critical and the reaction is usually carried out under cooling to warming.

Process (3)

The compound (I) or a salt thereof can be prepared by reaction the compound (IV) or a salt thereof with the compound (V) or a salt thereof.

The present reaction may be carried out in a solvent such as acetone, chloroform, acetonitrile, methylene chloride, ethylene chloride, formamide,

N,N-dimethylformamide, methanol, ethanol, diethyl ether, tetrahydrofuran, dimethyl sulfoxide, or any other organic solvent which does not adversely affect the reaction. The reaction temperature is not critical, and the reaction is usually carried out under cooling, at ambient temperature or under warming. The reaction may also be carried out in the presence of an inorganic base and an organic base such as an alkali metal [e.g. sodium, potassium, etc.], an alkaline earth metal [e.g. magnesium, calcium, etc.], the hydroxide or carbonate or bicarbonate thereof,

tri(lower)alkylamine [e.g. trimethylamine, triethylamine, diisopropylethylamine etc.], picoline, alkali metal alkanoate [e.g. sodium 2-ethylhexanoate, etc.],

N-(lower)alkylmorpholine, N,N-di(lower)alkyIbenzylamine, or the like.

Process (4)

The compound (Id) or a salt thereof can be prepared by subjecting the compound (Ic) or a salt thereof to elimination reaction of the carboxy protective group in R_a ⁶. This reaction can be carried out in a similar manner to that of the aforementioned Process (2), and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process (2). The present invention includes, within the scope of the invention, the case that the protected hydroxy group in R⁵ is transformed into a

hydroxy group during the reaction.

Process (5)

The compound (If) or a salt thereof can be prepared by subjecting the compound (Ie) or a salt thereof to

elimination reaction of the hydroxy protective group in R_a ⁵. This reaction can be carried out in a similar manner to that of the aforementioned Process (2), and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process (2).

Process (A)

The compound (VIIIa) or a salt thereof can be

prepared by reacting the compound (VI) or its reactive derivative at the carboxy group or a salt thereof with the compound (VII) or its reactive derivative or a salt thereof.

The reaction is usually carried out in a conventional solvent such as water, alcohols (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, chloroform, methylene chloride, dimethyl acetamide,

N,N-dimethylformamide or any other organic solvent which does not adversely influence the reaction. Among these solvents, hydrophilic solvents may be used in a mixture with water.

The reaction temperature is not critical and the reaction is usually carried out under cooling to warming.

Process (B)

The compound (V) or a salt thereof can be prepared by reacting the compound (VIII) or a salt thereof with the compound (IX) or a salt thereof.

N,N-dimethylformamide or any other organic solvent which does not adversely influence the reaction.

The reaction temperature is not critical and the reaction is usually carried out under cooling to heating.

Process (C)

The compound (Vb) or a salt thereof can be prepared by subjecting the compound (Va) or a salt thereof to introduction reaction of the carboxy protective group.

The introducing agent of a carboxy protective group to be used in this reaction may include a conventional esterifying agent such as an alcohol or its reactive derivative (e.g. halide, sulfonate, sulfate, diazo

compound, etc.), and the like. This reaction may also be carried out in the presence of an inorganic or organic base such as an alkali metal carbonate, tri(lower) alkylamine, pyridine, or the like.

This reaction is usually carried out in a

conventional solvent which does not adversely influence the reaction such as N,N-dimethylformamide, tetrahydrofuran, dioxane, methanol, ethanol, etc., or a mixture thereof.

In case that the alcohol is used as the introducing agent of a carboxy protective group, the reaction can be carried out in the presence of a condensing agent as

illustrated in Process (1). Process (D)

The compound (IIa) or a salt thereof can be prepared by reacting the compound (X) or a salt thereof with the compound (V) or a salt thereof.

The reaction is usually carried out in a conventional solvent such as alcohols (e.g., methanol, ethanol,

isopropyl alcohol, etc.), tetrahydrofuran, dioxane,

chloroform, methylene chloride, dimethyl acetamide,

N,N-dimethylformamide or any other organic solvent which does not adversely influence the reactionThe reaction temperature is not critical and the

reaction is usually carried out under cooling to warming.

This reaction may also be carried out in the presence of an inorganic or an organic base as defined in Process

(3).

Process (E)

The compound (IIe) or a salt thereof can be prepared by subjecting the compound (IIb) or a salt thereof to

elimination reaction of the carboxy protective group in

R CL This reaction can be carried out in a similar manner to that of the aforementioned Process (2), and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process (2).

The present invention includes, within the scope of the invention, the case that the protected hydroxy group in R⁵ is transformed into a hydroxy group during the reaction.

Process (F)

The compound (IIe) or a salt thereof can be prepared by subjecting the compound (IId) or a salt thereof to elimination reaction of the hydroxy protective group in R_a ⁵. This reaction can be carried out in a similar manner to that of the aforementioned Process (2), and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process (2).

Process (G)

The compound (II) or a salt thereof can be prepared by subjecting the compound (Ilf) or a salt thereof to elimination reaction of the amino protective group in R_a ⁹.

This reaction can be carried out in a similar manner to that of the aforementioned Process (2), and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process (2).

Suitable salts of the object and starting compounds and their reactive derivatives in Process (1)~(5) and

(A)~(G) can be referred to the ones as exemplified for the compound (I).

The object compound (I) and pharmaceutically

acceptable salts thereof are novel and exhibit high

antimicrobial activity, inhibiting the growth of a wide variety of pathogenic microorganisms including Gram positive and Gram-negative microorganisms and are useful as antimicrobial agents.

Now in order to show the utility of the object compound (I), the test data on MIC (minimal inhibitory concentration) of representative compound of this invention are shown in the following.

Test method :

In vitro antibacterial activity was determined by the two-fold agar-plate dilution method as described below.

One loopful of an overnight culture of each test strain in Trypticase-soy broth (10⁸ viable cells per ml) was streaked on heart infusion agar (HI-agar)containing graded concentrations of representative test compound, and the minimal inhibitory concentration (MIC) was expressed in terms of μg/ml after incubation at 37°C for 20 hours.

Test compound :

(1) 7β-[2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1- methylethoxyimino)acetamido]-3-[N,N-dimethyl-N-{2-(2- carboxy-4-oxo-5-hydroxy-1,4-dihydropyridin-1-yl)ethyl}- ammoniomethyl]-3-cephem-4-carboxylate (syn isomer)

Test result :

For therapeutic administration, the object compound

(I) and pharmaceutically acceptable salts thereof of the present invention are used in the form of conventional pharmaceutical preparation which contains said compound as an active ingredient, in admixture with pharmaceutically acceptable carriers such as an organic or inorganic solid or liquid excipient which is suitable for oral, parenteral and external administration.

The pharmaceutical preparations may be in solid form such as tablet, granule, powder, capsule, or liquid form such as solution, suspension, syrup, emulsion, lemonade and the like.

In needed, there may be included in the above

preparations, auxiliary substances, stabilizing agents, wetting agents and other commonly used additives such as lactose, citric acid, tartaric acid, stearic acid,

magnesium stearate, terra alba, sucrose, corn starch, talc, gelatin, agar, pectin, peanut oil, olive oil, cacao butter, ethylene glycol, and the like.

While the dosage of the compound (I) may vary from and also depend upon the age, conditions of the patient, a kind of diseases, a kind of the compound (I) to be

applied, etc. In general, amounts between 1 mg and about 4,000 mg or even more per day may be administered to a patient. An average single dose of about 50 mg, 100 mg, 250 mg, 500 mg, 1000 mg of the object compound (I) of the present invention may be used in treating diseases

infected by pathogenic microorganisms. Preferred embodiments of the object compound (I) are as follows.

R¹ is amino or acylamino,

Z is N or CH,

R² is hydrogen, lower alkyl.

carboxy(lower)alkyl, or

protected carboxy(lower)alkyl [more preferably esterified carboxy(lower)alkyl; most preferably lower alkoxycarbonyl(lower)alkyl],

R³ is lower alkyl. R⁴ is lower alkyl,

A is lower alkylene,

R⁵ is hydroxy, acyloxy, or phenyl(lower)alkoxy which may have one or more suitable substituent(s) [more preferably lower

alkoxyphenyl(lower)alkoxy], and

R⁶ is carboxy, esterified carboxy [more preferably phenyl(lower)alkyloxycarbonyl which may have one or more suitable substituent(s); most preferably benzhydryloxycarbonyl], carbamoyl, or mono or di(lower)alkylcarbamoyl.

The following Preparations and Examples are given for the purpose of illustrating the present invention in more detail.

Preparation 1

To a stirred suspension of 2-carboxy-4-oxo-5-{4- methoxybenzyloxy)-4H-pyran (20 g) in N,N-dimethylformamide (400 ml) were added 1-hydroxybenzotriazole (10.8 g) and N,N'-dicyclohexylcarbodiimide (16.4 g) at 5°C, and the mixture was stirred at the same temperature for 15

minutes. Then to the mixture was added 28% ammonia in water (5.5 ml) at the same temperature. The mixture was stirred at the same temperature for 4 hours, and at room temperature for 4 hours. The mixture was poured into water, and adjusted to pH 9 with 1N sodium hydroxide to give the precipitate. The precipitate was collected by filtration, and washed with water. The precipitate was added to ethyl acetate at room temperature, and the

suspension was stirred at the same temperature for 15 minutes. The insoluble material was collected by

filtration and washed with ethyl acetate. The insoluble material was dried under reduced pressure to give crude 2-carbamoyl-4-oxo-5-(4-methoxybenzyloxy)-4H-pyran (32.7 g). IR (Nujol) : 1645, 1620 cm^-1

NMR (DMSO-d₆, d) : 3.76 (3H, s), 4.91 (2H, s),

6.87 (1H, s), 6.96 (2H, d, J-=8.7Hz), 7.36 (d, J=8.7Hz), 8.04 (1H, br s), 8.20 (1H, s),

8.31 (1H, br s)

Preparation 2

To a stirred suspension of 2-carboxy-4-oxo-5-(4- methoxybenzyloxy)-4H-pyran (10 g) in N,N-dimethylformamide (200 ml) were added 1-hydroxybenzotriazole (5.4 g) and N,N^,-dicyclohexylcarbodiimide (8.2 g) at 5°C, and the mixture was stirred at the same temperature for 30

minutes. Then to the mixture was added 50% dimethylamine in water (3.59 g) at the same temperature. The mixture was stirred at the same temperature for 3 hours, and at room temperature for 6 hours. The mixture was poured into water, and adjusted to pH 8 with 1N sodium hydroxide.

After extracted with chloroform, the organic layer was washed with water, dried with magnesium sulfate, filtered and evaporated under reduced pressure. To the residue was added isopropyl alcohol, and the mixture was stirred at room temperature for 1 hour. The insoluble material was collected by filtration, washed with isopropyl alcohol and dried under reduced pressure to give

2-(N,N-dimethylcarbamoyl)-4-oxo-5-(4-methoxybenzyloxy)-4H-pyran (7.60 g).

NMR (DMSO-d₆, 6) : 2.96 (3H, s), 2.99 (3H, s),

3.77 (3H, s), 4.88 (2H, s), 6.59 (1H, s),

6.95 (2H, d, J=8.7Hz), 7.36 (2H, d, J=8.7Hz), 8.28 (1H, s)

Preparation 3

To a stirred suspension of 2-carboxy-4-oxo-5-(4-methoxybenzyloxy)-4H-pyran (268 g) in ethanol (2.7 l ) was added N,N-dimethylethylenediamine (400 ml) at room temperature, and the solution was refluxed for 2 hours. After removal of ethanol under reduced pressure, the residue was purified by column chromatography on silica gel (acetone/water as eluent) to give 1-[2-(N,N-dimethyl- amino)ethyl]-2-carboxy-4-oxo-5-(4-methoxybenzyloxy)-1,4- dihydropyridine. To a stirred solution of the product in N,N-dimethylformamide (1 ℓ) was added diphenyldiazomethane (565 g) at room temperature, and the solution was warmed to 60ºC and then stirred at the same temperature for 12 hours. The solution was poured into water, and extracted with ethyl acetate. The organic layer was washed with water, and then to the organic layer was added acetic acid (110 ml) to decompose excess diphenyldiazomethane, and the mixture was stirred at room temperature for 2 hours. Then the solution was adjusted to pH 10 with an aqueous

solution of N-sodium hydroxide. After separation, the organic layer was washed with brine and concentrated under reduced pressure. To the residue was added hexane to give a precipitate. After filtration, the precipitate was washed with hexane and dried in vacuo to give 1-[2-(N,N- dimethylaraino)ethyl]-2-benzhydryloxycarbonyl-4-oxo-5-(4- methoxybenzyloxy)-1,4-dihydropyridine (199 g).

NMR (DMSO-d₆, δ) : 1.85 (6H, s), 2.28 (2H, m),

3.74 (3H, s), 4.20 (2H, m), 4.97 (2H, s),

6.75 (1H, s), 6.91-7.54 (15H, m), 7.69 (1H, s)

Preparation 4

(1) To a stirred suspension of 2-carbamoyl-4-oxo-5-(4-methoxybenzyloxy)-4H-pyran (32.7 g) in ethanol (33 ml) was added N,N-dimethylethylenediamine (19.5 ml) at room

temperature, and the mixture was refluxed for 4 hours.

After removal of ethanol under reduced pressure, the residue was purified by column chromatography on silica gel (acetone/water as eluent) to give 2-carbamoyl-1-[2-(N,N-dimethylamino)ethyl]-4-oxo-5-(4-methoxybenzyloxy)- 1,4-dihydropyridine (12.95 g).

NMR (DMSO-d₆, δ) : 2.10 (6H, s), 2.46 (2H, t,

J=6.3Hz), 3.75 (3H, s), 4.09 (2H, t, J=6.3Hz), 4.95 (2H, s), 6.25 (1H, s), 6.93 (2H, d,

J=8.7Hz), 7.33 (2H, d, J=8.7Hz), 7.56 (1H, s), 7.90 (1H, br s), 8.30 (1H, br s)

The following compound was obtained according to a similar manner to that of Preparation 4-(1).

(2) 1-[2-(N,N-Dimethylamino)ethyl]-2-(N,N- dimethylcarbamoyl)-4-oxo-5-(4-methoxybenzyloxy)-1,4- dihydropyridine

NMR (DMSO-d₆, δ) : 2.08 (6H, s), 2.38-2.52 (2H, m), 2.93 (3H, s), 2.97 (3H, s), 3.75 (3H, s),

3.80-4.18 (2H, m), 4.93 (2H, s), 6.10 (1H, s), 6.94 (2H, d, J=8.7Hz), 7.34 (2H, d, J=8.7Hz), 7.62 (1H, s) Preparation 5

To an ice-cooled solution of 1-[2-(N,N-dimethylamino)ethyl]-2-benzhydryloxycarbonyl-4-oxo-5- (4-methoxybenzyloxy)-1,4-dihydropyridine (2.0 g) and sodium 2-ethylhexanoate (0.65 g) in N,N-dimethylformamide (10 ml) was added 7β-formamido-3-chloromethyl-3-cephem-4-carboxylic acid (1.07 g). After stirred at the same temperature for 1.5 hours, the reaction mixture was poured into a mixture of isopropyl ether (50 ml) and ethyl acetate (50 ml). The resulting precipitate was collected by filtration, washed with isopropyl ether and dried in vacuo. The dried precipitate (2.0 g) was suspended in dichloromethane (4 ml) and anisole (4 ml).

Trifluoroacetic acid (10 ml) was dropwise added to the above suspension under ice-cooling. The mixture was stirred at 5°C for an hour and poured into isopropyl ether (100 ml). The resulting precipitate was collected by filtration, washed with ethyl acetate and dried in vacuo to give 7β-formamido-3-[N,N-dimethyl-N-{2-(2-carboxy-4- oxo-5-hydroxy-1,4-dihydropyridin-1-yl)ethyl}- ammoniomethyl]-3-cephem-4-carboxylate trifluoroacetate (1.44 g).

IR (Nujol) : 1780, 1665, 1610 cm^-1

NMR (DMSO-d₆, δ) : 3.11 (3H, s), 3.20 (3H, s),

3.43, 3.91 (2H, ABq, J=16.8Hz), 3.75 (2H, m), 4.38, 4.83 (2H, ABq, J=13.5Hz), 4.80 (2H, m),

5.28 (1H, d,.J=5Hz), 5.85 (1H, dd, J=8Hz), 6.96 (1H, s), 7.94 (1H, s), 8.15 (1H, s),

9.20 (1H, d, J=8Hz) Preparation 6

To a mixture of 7β-formamido-3-[N,N-dimethyl-N-{2-(2- carboxy-4-oxo-5-hydroxy-1,4-dihydropyridin-1-yl)ethyl}- ammoniomethyl]-3-cephem-4-carboxylate trifluoroacetate (1.40 g) and methanol (28 ml) was added cone, hydrochloric acid (1.32 ml) with stirring. After stirred at 25°C for 5 hours, the reaction mixture was poured into acetone (140 ml). The resulting precipitate was collected by

filtration and dried in vacuo. The dried powder (0.75 g) was dissolved into water (7.5 ml) and subjected to column chromatography on Diaion HP-20 (30 ml) (trademark :

Mitsubishi Kasei Corporation). The elution was carried out with water and the fractions containing the object compound (23 ml) were collected. To the ice-cooled solution obtained above was added isopropyl alcohol (69 ml) slowly. The resulting precipitate was collected by filtration and dried in vacuo to give

7β-amino-3-[N,N-dimethyl-N-{2-(2-carboxy-4-oxo-5-hydroxy-1,4-dihydropyridin-1-yl)ethyl}ammoniomethyl]-3-cephem-4-carboxylate dihydrcchloride (0.22 g).

IR (Nujol) : 3330, 1775, 1607 cm^-1 NMR (D₂O, δ) : 3.19 (3H, s), 3.25 (3H, s), 3.60, 4.05 (2H, ABq, J=16.8Hz), 3.95 (2H, m), 4.23, 4.83 (2H, ABq, J=13.5Hz), 4.98 (2H, m), 5.22 (1H, d, J=5Hz), 5.44 (1H, d, J=5Hz), 7.32 (1H, s), 8.05 (1H, s)

Example 1

To a solution of 7β-amino-3-[N,N-dimethyl-N-{2-(2- carboxy-4-oxo-5-hydroxy-1,4-dihydropyridin-1-yl)ethyl}- ammoniomethyl]-3-cephem-4-carboxylate dihydrochloride

(0.20 g) in a mixture of tetrahydrofuran (10 ml) and water (10 ml) was dropwise added a solution of

2-(5-amino-1,2,4-thiadiazol-3-yl)-2-methoxyiminoacetyl chloride hydrochloride (syn isomer) (0.16 g) in

tetrahydrofuran (2 ml) at 15-20°C. During the reaction, the pH of reaction mixture was kept between 5.0 and 5.5 with an aqueous solution saturated with sodium

bicarbonate. After 30 minutes, the mixture was adjusted to pH 6.0 with an aqueous solution saturated with sodium bicarbonate and stirred at 20ºC for 6 hours. After

evaporation of organic solvent under reduced pressure, the aqueous solution was diluted with water (30 ml) and

adjusted to pH 1.0 with 6N hydrochloric acid. The

resulting aqueous solution (40 ml) was subjected to column chromatography on Diaion HP-20 (20 ml). After the column was washed with water, the elution was carried out with 30% aqueous methanol. The fraction containing the object compound was freeze-dried to give 7β-{2-(5-amino-1,2,4-thiadiazol-3-yl)-2-methoxyiminoacetamido}-3-[N,N-dimethyl-N-{2-(2-carboxy-4-oxo-5-hydroxy-1,4-dihydropyridin-1-yl)-ethyl}ammoniomethyl]-3-cephem-4-carboxylate (syn isomer) (0.13 g).

IR (Nujol) : 1760, 1640 (sh), 1602 cm^-1

NMR (D₂O-NaHCO₃, δ) : 3.13 (3H, s), 3.17 (3H, s),

3.46, 3.94 (2H, ABq, J=17Hz), 3.80 (2H, m), 4.08 ( 2H, m) , 4.12 , 4.76 ( 2H, ABq, J=13.5Hz ) , 4.80 ( 2H, m) , 5.37 ( 1H, d, J=5Hz) , 5.90 ( 1H, d, J=5Hz) , 6.68 (1H, s) , 7.28 ( 1H, s) Example 2

To a solution of 7β-amino-3-[N,N-dimethyl-N-{2-(2- carboxy-4-oxo-5-hydroxy-1,4-dihydropyridin-1-yl)ethyl}- ammoniomethyl]-3-cephem-4-carboxylate dihydrochloride (0.50 g) in a mixture of tetrahydrofuran (15 ml) and water (15 ml) was dropwise added a solution of

S-2-benzothiazolyl-2-(2-aminothiazol-4-yl)-2-(1-tert- butoxycarbonyl-1-methylethoxyimino)ethanethioate (syn isomer) (0.70 g) in tetrahydrofuran (10 ml) at 20ºC.

After stirred for 6 hours at the same temperature, the reaction mixture was diluted with water (30 ml) and ethyl acetate (30 ml) and adjusted to pH 7.0 with an aqueous solution saturated with sodium bicarbonate. The separated aqueous layer was washed with ethyl acetate (30 ml) three times. After adjusted to pH 1.0 with 6N hydrochloric acid, the aqueous layer was subjected to column

chromatography on Diaion HP-20 (50 ml). The object compound was eluted with 50% aqueous methanol, and the fractions containing the object compound were freeze-dried to give 7β-[2-(2-aminothiazol-4-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyiminoacetamido]-3-[N,N-dimethyl-N- {2-(2-carboxy-4-oxo-5-hydroxy-1,4-dihydropyridin-1-yl)-ethyl}ammoniomethyl]-3-cephem-4-carboxylate (syn isomer) (0.33 g). The compound (0.30 g) obtained above was

suspended in anisole (2 ml) and trifluoroacetic acid (6 ml) was added under ice-cooling with stirring. After stirred for 3 hours at ambient temperature, the mixture was poured into diisopropyl ether (100 ml). The resulting precipitate was collected by filtration, washed with diisopropyl ether and dried under reduced pressure. The dried precipitate was dissolved in water (60 ml) at pH 1.0. The aqueous solution was subjected to column

chromatography on Diaion HP-20 (20 ml). After the column was washed with water, the object compound was eluted with 30% aqueous methanol and freeze-dried to give 7β-[2-(2- aminothiazol-4-yl)-2-(1-carboxy-1-methylethoxyimino)- acetamido]-3-[N,N-dimethyl-N-{2-(2-carboxy-4-oxo-5- hydroxy-l,4-dihydropyridin-1-yl)ethyl}ammoniomethyl]-3- cephem-4-carboxylate (syn isomer) (0.19 g).

IR (Nujol) : 3220, 1772, 1650 (sh.), 1609 cm^-1

NMR (D₂O-NaHCO₃, δ) : 1.49 (3H, s), 1.50 (3H, s),

3.13 (3H, s), 3.18 (3H, s), 3.48, 3.94 (2H, ABq, J=16.8Hz), 4.14, 4.74 (2H, ABq, J=13.5Hz), 4.70 (2H, m), 5.39 (1H, d, J=5Hz), 5.87 (1H, d, J=5Hz), 6.71 (1H, s), 6.97 (1H, s), 7.39 (1H, s)

Example 3

(1) To a stirred solution of 1-[2-(N,N-dimethylamino)- ethyl]-2-benzhydryloxycarbonyl-4-oxo-5-(4-methoxybenzyloxy)-1,4-dihydropyridine (30 g) and

diisopropylethylamine (25.3 ml) in N,N-dimethylformamide (150 ml) was added 7β-[2-(5-amino-1,2,4-thiadiazol-3-yl)- 2-(1-carboxy-1-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-carboxylie acid trifluoroacetate (syn isomer) (30 g) at 3ºC, and the solution was stirred at the same temperature for 2 hours. The solution was poured into ethyl acetate (1.5 ℓ) to give a precipitate. After filtration, the precipitate was washed with ethyl acetate followed by diethyl ether, and dried in vacuo to give 7β-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-[N,N-dimethyl-N-[2-{2-benzhydryloxycarbonyl-4-oxo-5-(4-methoxybenzyloxy)-1,4-dihydropyridin-1-yl}ethyl]ammoniomethyl]-3-cephem-4-carboxylate (syn isomer). To a stirred suspension of this compound in anisole (230 ml) was added trifluoroacetic acid (306 ml) dropwise over 30 minutes under ice-cooling, and the solution was stirred at 3°C for 1 hour. The solution was poured into diisopropyl ether (3 ℓ) to give a precipitate and the precipitate was collected by

filtration. The precipitate was washed with diisopropyl ether followed by diethyl ether. After dried in vacuo, the powder was dissolved into water at pH 6.5. The aqueous solution was subjected to column chromatography on Diaion HP-20 (100 ml). The desired product was eluted with water. The eluate was adjusted to pH 1 with 6N hydrochloric acid, and the resulting precipitate was removed by filtration. The filtrate was subjected to column chromatography on Diaion HP-20 (1.7 ℓ) and eluted with 30% aqueous methyl alcohol. The fractions containing the desired product were combined and evaporated under reduced pressure to remove methyl alcohol. The residue was lyophilized to give 7β-[2-(5-amino-1,2,4-thiadiazol- 3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3- [N,N-dimethyl-N-{2-(2-carboxy-4-oxo-5-hydroxy-1,4- dihydropyridin-1-yl)ethyl}ammoniomethyl]-3-cephem-4- carboxylate (syn isomer) (9.39 g).

IR (Nujol) : 1760, 1645 (sh.), 1600 cm^-1

NMR (D₂O-NaHCO₃, δ) : 1.52 (3H, s), 1.53 (3H, s),

3.13 (3H, s), 3.19 (3H, s), 3.47, 3.93 (2H, ABq, J=16.8Hz), 3.83 (2H, m), 4.13, 4.75 (2H, ABq,

J=13.5Hz), 4.8 (2H, m), 5.39 (1H, d, J=5.0Hz), 5.90 (1H, d, J=5.0Hz), 6.74 (1H, s), 7.58 (1H, s) ihe following compounds were obtained according to a similar manner to that of Example 3-(l).

(2) 7β-[2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-[N,N-dimethyl-N-{2-(2-carbamoyl-4-oxo-5-hydroxy-1,4-dihydropyridin-1-yl)ethyl}- airimoniomethyl ] -3-cephem-4-carboxylate ( syn isomer) .

IR (Nujol ) : 1765 , 1665 cm^-1

NMR (D₂O-NaHCO₃ , δ ) : 1.53 ( 6H, s ) , 3.16 ( 6H, d,

J=12.2Hz ) , 3.44-4.80 ( 8H, m) , 5.39 ( 1H, d,

J=5.0Hz ) , 5.85 ( 1H, d, J=5.0Hz ) , 6.81 ( 1H, s ) ,

7.68 ( 1H, s )

(3) 7β-[2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1- carboxy-1-methylethoxyimino)acetamido]-3-[N,N-dimethyl- N-[2-{2-(N,N-dimethylcarbamoyl)-4-oxo-5-hydroxy-1,4- dihydropyridin-1-yl}ethyl]ammoniomethyl]-3-cephem-4- carboxylate (syn isomer).

IR (Nujol) : 1770, 1655, 1625 cm^-1

NMR (D₂O-NaHCO₃, δ) : 1.53 (6H, s), 3.05-3.18 (12H, m), 3.34-4.91 (8H, m), 5.39 (1H, d, J=5.0Hz),

5.88 (1H, d, J=5.0Hz), 6.60 (1H, s), 7.73 (1H, s)

Example 4

To a mixture of ethanol (1 ml) and IN hydrochloric acid (2.52 ml) was added 7β-[2-(5-amino-1,2,4-thiadiazol- 3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3- [N,N-dimethyl-N-{2-(2-carboxy-4-oxo-5-hydroxy-1,4-dihydropyridin-1-yl)ethyl}ammoniomethyl]-3-cephem-4-carboxylate (syn isomer) (0.50 g) at 20°C. The clear solution of the mixture was cooled with ice, and

ethanol (6.5 ml) was added thereto. After the mixture was stirred for 2 hours, the resulting precipitate was

collected by filtration, washed with ethanol and dried in vacuo to give 7β-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-[N,N-dimethyl-N-{2-(2-carboxy-4-oxo-5-hydroxy-1,4-dihydropyridin-1-yl)ethyl}ammoniomethyl]-3-cephem-4-carboxylate hydrochloride (syn isomer).

IR (Nujol) : 3300, 2700-2500 (br), 1770, 1715, 1665,

1600 cm^-1 NMR (DMSO-d₆, δ) : 1.46 (6H, s), 3.12 ( 3H, s), 3.22 (3H, s), 3.70, 4.06 (2H, ABq, J=17.4Hz), 3.8-4.1 (2H, m), 4.45, 4.65 (2H, ABq, J=13.3Hz), 5.0 (2H, m), 5.35 (1H, d, J=5Hz), 5.95 (1H, dd, J=5Hz, 8Hz), 7.61 (1H, s), 8.3 (2H, br s), 8.39

(1H, s), 9.59 (1H, d, J=8Hz)

Example 5

To a mixture of 1M aqueous sulfuric acid (30.2 ml) and ethanol (20 ml) was added 7β-[2-(5-amino-1,2,4- thiadiazbl-3-yl)-2-(1-carboxy-1-methylethoxyimino)- acetamido]-3-[N,N-dimethyl-N-{2-(2-carboxy-4-oxo-5- hydroxy-1,4-dihydropyridin-1-yl)ethyl}ammoniomethyl3-3- cephem-4-carboxylate (syn isomer) (6 g) at 20-25^eC.

Ethanol (70 ml) was dropwise added to the above solution for 80 minutes. After the mixture was stirred at the same temperature for 2 hours, the resulting precipitate was collected by filtration, washed with ethanol and dried in vacuo to give 7β-[2-(5-amino-l,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido3-3-[N,N-dimethyl-N-(2-(2-carboxy-4-oxo-5-hydroxy-1,4-dihydropyridin-1-yl)-ethyl}ammoniomethyl]-3-cephem-4-carboxylate sulfate (syn isomer) (4.6 g).

IR (Nujol) : 3300, 2800-2500 (br), 1773, 1715, 1670,

1600, 1160 cm^-1

NMR (DMSO-d_g, δ) : 1.46 (6H, s), 3.07 (3H, s), 3.16 (3H, s), 3.68, 3.98 (2H, ABq, J=17.3Hz), 3.7-3.9 (2H, m), 4.33, 4.69 (2H, ABq, J=13.2Hz), 4.8 (2H, m), 5.30 (1H, d, J=5Hz), 5.97 (1H, dd,

J=5Hz, 8Hz), 7.02 (1H, s), 7.88 (1H, s), 8.22

(2H, br s), 9.58 (1H, dd, J=5Hz, 8Hz)

Claims

C L A I M S 1. A compound of the formula :

wherein R¹ is amino or protected amino,

Z is N or CH,

R² is hydrogen or an organic group,

R³ is lower alkyl,

R⁴ is lower alkyl,

A is lower alkylene,

R⁵ is hydroxy or protected hydroxy, and R⁶ is carboxy, protected carboxy, carbamoyl, or mono or di substituted carbamoyl, or pharmaceutically acceptable salts thereof.

A compound of claim 1, wherein

R¹ is amino or acylamino.

R² is hydrogen,lower alkyl, carboxy(lower)alkyl, or protected carboxy(lower)alkyl,

R⁵ is hydroxy, acyloxy, or phenyl(lower)alkyloxy

which may have one or more suitable substituent(s), and

R⁶ is carboxy, esterified carboxy, carbamoyl, or

mono or di( lower)alkylcarbamoyl.

3. A compound of claim 2, wherein

R² is lower alkyl, carboxy(lower)alkyl, or

esterified carboxy(lower)alkyl,

R5 is hydroxy, acyloxy, or lower alkoxyphenyl(lower)alkoxy, and

R⁶ is carboxy, phenyl(lower)alkyloxycarbonyl which may have one or more suitable substituent(s), carbamoyl, or di(lowerJalkylcarbamoyl.

4. A compound of claim 3, wherein

R² is lower alkyl, carboxy(lower)alkyl, or lower

alkoxycarbonyl(lower)alkyl, and

R⁶ is carboxy, benzhydryloxycarbonyl, carbamoyl, or di(lower)alkylcarbamoyl

5. A compound of claim 4, wherein

R¹ is amino,

Z is N,

R² is carboxy(lower)alkyl,

R⁵ is hydroxy, and

R⁶ is carboxy.

6. A compound of claim 5, which is

7β-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1- methylethoxyimino)acetamido]-3-[N,N-dimethyl-N-{2-(2- carboxy-4-oxo-5-hydroxy-1,4-dihydropyridin-1-yl)- ethyl}ammoniomethyl]-3-cephem-4-carboxylate ( syn isomer).

7. A process for preparing a compound of the formula

wherein R¹ is amino or protected amino,

Z is N or CH, R² is hydrogen or an organic group,

R³ is lower alkyl,

R⁴ is lower alkyl,

A is lower alkylene,

R⁵ is hydroxy or protected hydroxy, and R⁶ is carboxy, protected carboxy, carbamoyl, or mono or di substituted carbamoyl, or a salt thereof,

which comprises.

(1) reacting a compound of the formula

wherein R³, R⁴, R⁵, R⁶ and A are each as defined

above,

or its reactive derivative at the amino group or a salt thereof with a compound of the formula

wherein R¹, R² and Z are each as defined above, or its reactive derivative at the carboxy group or a salt thereof to give a compound of the formula

wherein R¹, R², R³, R⁴, R⁵, R⁶, Z and A are each as defined above,

or a salt thereof, or

(2) subjecting a compound of the formula :

wherein R¹, R³ , R⁴, R⁵, R⁶, Z and A are each as

defined above,

R_a ² is protected carboxy(lower)alkyl, or a salt thereof to elimination reaction of the carboxy protective group in R_a ² to give a compound of the formula

wherein R¹, R³, R⁴, R⁵, R⁶, Z and A are each as

defined above.

R_b ² is carboxy(lower)alkyl,

or a salt thereof, or (3 ) reacting a compound of the formula :

wherein R ¹, R² and Z are each as defined above,

Y is a leaving group,

or a salt thereof with a compound of the formula

wherein R³, R⁴, R⁵, R⁶ and A are each as defined above,

or a salt thereof to give a compound of the formula

wherein R¹, R², R³, R⁴, R⁵, R⁶, Z and A are each as defined above,

or a salt thereof, or

(4) subjecting a compound of the formula

wherein R¹ , R² , R³ , R⁴ , R⁵ , Z and A are each as

defined above,

R_a ⁶ is protected carboxy,

or a salt thereof to elimination reaction of the carboxy protective group in R_a ⁶ to give a compound of the formula :

wherein R¹, R², R³, R⁴, R⁵, Z and A are each as

defined above,

or a salt thereof, or

(5) subjecting a compound of the formula :

wherein R¹, R², R³, R⁴, R⁵, Z and A are each as

defined above,

R_a ⁵ is protected hydroxy,

or a salt thereof to elimination reaction of the hydroxy protective group in R_a ⁵ to give a compound of the formula :

wherein R¹, R², R³, R⁴, R⁶, Z and A are each as

defined above,

or a salt thereof.

8. A pharmaceutical composition which comprises, as an active ingredient, a compound of claim 1 or a pharmaceutically acceptable salt thereof in admixture with pharmaceutically acceptable carriers.

9. A method for the treatment of infectious diseases

which comprises administering a compound of claim 1 or a pharmaceutically acceptable salt thereof to human or animals.

10. A compound of claim 1 or a pharmaceutically

acceptable salt thereof for use as an antimicrobial agent.